HER-2阳性乳腺癌新型靶向治疗的研究进展

Human epidermal growth factor receptor 2(HER-2) positive breast cancer accounts for 15%～20% of breast cancer. It has attracted much attention because of its strong invasion and poor prognosis. Since the first HER-2 targeted drug trastuzumab was introduced, the treatment in this field has rapidly developed. This article will systematically describe the research progress of targeted drugs for HER-2 positive breast cancer: The emergence of monoclonal antibodies has laid the foundation for the treatment of early and advanced patients. The dual target combination regimen significantly improved the pathological complete response and long-term disease-free survival rate of early breast cancer patients. The emergence of antibody drug conjugates(ADC) has shown excellent efficacy in advanced multi-line therapy, significantly improving long-term survival of patients and promoting the advancement of treatment line level. This article focuses on the clinical application plan of targeted drugs, with a particular emphasis on exploring the optimization path of their treatment strategies, while also looking forward to the application prospects of artificial intelligence assisted decisionmaking in personalized treatment plan optimization. This review aims to provide comprehensive references for clinical practice and new ideas for basic and translational research in this field.